Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients

Scott E. Strome, Elizabeth Martin, Dallas Flies, Dianne Khurana, Diva Salomao, Koji Tamada, Andrei I. Chapoval, Jan L. Kasperbauer, Kerry D. Olsen, Lieping Chen

Research output: Contribution to journalArticlepeer-review


OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells. STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status. RESULTS: CD62L Low T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10. CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin. SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.

Original languageEnglish (US)
Pages (from-to)180-187
Number of pages8
JournalOtolaryngology - Head and Neck Surgery
Issue number2
StatePublished - Feb 2002

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology


Dive into the research topics of 'Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients'. Together they form a unique fingerprint.

Cite this